Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
June 01 2016 - 6:00AM
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that
Linda Neuman, M.D., has been appointed to the role of Vice
President, Clinical Development. Dr. Neuman brings 10 years of
clinical practice and 13 years of industry experience to Sunesis,
most recently serving as Senior Medical Director of Oncology at
Puma Biotechnology.
“Linda is a demonstrated leader who has driven
research success through team building, clinical strategy and
execution at all phases of drug development,” said Daniel Swisher,
Chief Executive Officer of Sunesis. “Her insights and experience
are welcome additions to the team as we look to advance vosaroxin
to European marketing approval, and accelerate the development of
our kinase inhibitor pipeline, including our unique non-covalently
binding BTK inhibitor, SNS-062.”
“I was drawn to this opportunity by the depth
and potential of Sunesis’ pipeline,” stated Dr. Neuman. “Each of
our clinical assets has the potential to address significant areas
of unmet medical need in the treatment of cancer. I look
forward to working with Sunesis’ entrepreneurial team to advance
these programs to the market.”
At Puma Biotechnology, Dr. Neuman contributed to
the development strategy for neratinib, a tyrosine kinase inhibitor
under investigation for the treatment of breast cancer and other
solid tumors. Prior to joining Puma in 2015, Dr. Neuman spent three
years as Medical Director of Oncology at Onyx Pharmaceuticals,
where she served as clinical lead on the global product development
team, designing and implementing clinical development strategies on
multiple development projects as well as interacting with
regulators. Prior to joining Onyx, Dr. Neuman held roles of
increasing responsibility at Covidien Pharmaceuticals, Millennium
Pharmaceuticals and Schering-Plough.
Dr. Neuman obtained her medical degree from
Southern Illinois University, where she also received her Bachelor
of Science in biology. Dr. Neuman also holds a Master in Business
Administration from Indiana Wesleyan University.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people
with cancer and is currently pursuing regulatory approval in Europe
for its lead product candidate, vosaroxin, for the treatment of
relapsed or refractory acute myeloid leukemia in patients aged 60
and older. In addition, the company is advancing its
kinase-inhibitor pipeline of novel targeted therapies into the
clinic.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to Sunesis' corporate
objectives, including the anticipated progress and potential
approval of vosaroxin by the EMA, clinical development of SNS 062,
potential ex-US partnership, the expected progress in its kinase
inhibitor pipeline, and the sufficiency of Sunesis’ cash resources.
Words such as “expect,” “look forward,” "potential," "will" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon
Sunesis' current expectations. Forward-looking statements involve
risks and uncertainties. Sunesis' actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk that
Sunesis may not be able to receive regulatory approval of vosaroxin
in the U.S. or Europe, that Sunesis' development activities
for vosaroxin could be otherwise halted or significantly delayed
for various reasons, the risk that Sunesis' clinical studies for
vosaroxin or other product candidates, including its pipeline of
kinase inhibitors, may not demonstrate safety or efficacy or lead
to regulatory approval, the risk that data to date and trends may
not be predictive of future data or results, risks related to the
conduct of Sunesis' clinical trials, risks related to Sunesis' need
for substantial additional funding to complete the development and
commercialization of vosaroxin and other product candidates, and
risks related to Sunesis' ability to raise the capital that it
believes to be accessible and is required to fully finance the
development and commercialization of vosaroxin and other product
candidates. These and other risk factors are discussed under "Risk
Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for
the year ended December 31, 2015, Sunesis’ Quarterly Report on
Form 10-Q for the quarter ended March 31, 2016, when
available, and Sunesis' other filings with the Securities and
Exchange Commission. Sunesis expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Sunesis' expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024